Share Email Print

Proceedings Paper

Evaluation of anti-hepatocarcinoma capacity of puerarin nanosuspensions against human HepG2 cells
Author(s): Xiang-Ping Meng; Zhen Zhang; Yi-Fei Wang; Zhi-ping Wang; Tong-sheng Chen
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

Hepatocarcinoma, a malignant cancer, threaten human life badly. It is a current issue to seek the effective natural remedy from plant to treat cancer due to the resistance of the advanced hepatocarcinoma to chemotherapy. Puerarin (Pue), a major active ingredient in the traditional Chinese medicine Gegen, has a wide range of pharmacological properties and is considered to have anti-hepatocarcinoma effects. However its low oral bioavailability restricts its wide application. In this report, Pue nanosuspension (Pue-NS) composed of Pue and poloxamer 188 was prepared by high pressure homogenization technique. The in vitro anti-hepatocarcinoma effects of Pue-NS relative to efficacy of bulk Pue were evaluated. The particle size and zeta potential of Pue-NS were 218.5 nm and −18.8 mV, respectively. MTT assay showed that Pue-NS effectively inhibited the proliferation of HepG2 cells, and the corresponding IC50 values of Pue-NS and bulk Pue were 3.39 and 5.73 μg/ml. These results suggest that the delivery of Pue-NS is a promising approach for treating tumors.

Paper Details

Date Published: 20 February 2017
PDF: 7 pages
Proc. SPIE 10065, Biophotonics and Immune Responses XII, 100650U (20 February 2017); doi: 10.1117/12.2251116
Show Author Affiliations
Xiang-Ping Meng, Medical Technology and Engineering College, Henan Univ. of Science and Technology (China)
Zhen Zhang, School of Pharmacy, Guangdong Pharmaceutical Univ. (China)
Yi-Fei Wang, Institute of Biological Medicine, Jinan Univ. (China)
Zhi-ping Wang, School of Pharmacy, Guangdong Pharmaceutical Univ. (China)
Tong-sheng Chen, Institute of Laser Life Science, South China Normal Univ. (China)

Published in SPIE Proceedings Vol. 10065:
Biophotonics and Immune Responses XII
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top
Sign in to read the full article
Create a free SPIE account to get access to
premium articles and original research
Forgot your username?